

DAFTAR PUSTAKA

- Ahmad, T., Valentovic, M. A., & Rankin, G. O. (2018). Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics. *Biochemical Pharmacology*, 153, 196–204. <https://doi.org/10.1016/j.bcp.2018.02.020>
- Al Saad, S., Al Shenawi, H., Almarabheh, A., Al Shenawi, N., Mohamed, A. I., & Yaghan, R. (2022). Is laterality in breast cancer still worth studying? Local experience in Bahrain. *BMC Cancer*, 22(1), 968. <https://doi.org/10.1186/s12885-022-10063-y>
- Al-Wahiby, S., & Slijepcevic, P. (2005). Chromosomal aberrations involving telomeres in BRCA1 deficient human and mouse cell lines. *Cytogenetic and Genome Research*, 109(4), 491–496. <https://doi.org/10.1159/000084208>
- Amer, M. (2014). Genetic factors and breast cancer laterality. *Cancer Management and Research*, 191. <https://doi.org/10.2147/CMAR.S60006>
- Azhar, Y., Agustina, H., Abdurahman, M., & Achmad, D. (2020). Breast cancer in West Java: where do we stand and go? *Indonesian Journal of Cancer*, 14(3), 91. <https://doi.org/10.33371/ijoc.v14i3.737>
- Banik, U., Parasuraman, S., Adhikary, A. K., & Othman, N. H. (2017). Curcumin: The spicy modulator of breast carcinogenesis. *Journal of Experimental & Clinical Cancer Research*, 36(1), 98. <https://doi.org/10.1186/s13046-017-0566-5>
- Bogdanova, N., Helbig, S., & Dörk, T. (2013). Hereditary breast cancer: Ever more pieces to the polygenic puzzle. *Hereditary Cancer in Clinical Practice*, 11(1), 12. <https://doi.org/10.1186/1897-4287-11-12>
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 68(6), 394–424. <https://doi.org/10.3322/caac.21492>
- Burns, M., Foster, L., & Walker, M. (Eds.). (2020). *DNA techniques to verify food authenticity: Applications in food fraud*. Royal Society of Chemistry.
- Cao, A.-Y., Yu, K.-D., Yin, W.-J., Jin, W., Di, G.-H., Shen, Z.-Z., & Shao, Z.-M. (2010). Five common single nucleotide polymorphisms in the *PALB2* gene and susceptibility to breast cancer in eastern Chinese population. *Breast Cancer Research and Treatment*, 123(1), 133–138. <https://doi.org/10.1007/s10549-009-0637-1>
- Chappuis, P. O., Nethercot, V., & Foulkes, W. D. (2000). Clinico-pathological characteristics of *BRCA1*- and *BRCA2*-related breast cancer. *Seminars in Surgical Oncology*, 18(4), 287–295. [https://doi.org/10.1002/\(SICI\)1098-2388\(200006\)18:4<287::AID-SSU3>3.0.CO;2-5](https://doi.org/10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.0.CO;2-5)
- Chen, P., Liang, J., Wang, Z., Zhou, X., Chen, L., Li, M., Xie, D., Hu, Z., Shen, H., & Wang, H. (2008). Association of common *PALB2* polymorphisms with breast cancer risk: a case-control study. *Clinical Cancer Research*, 14(18), 5931–5937. <https://doi.org/10.1158/1078-0432.CCR-08-0429>
- Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P., Olson, J. E., Godwin, A. K., Pankratz, V. S., Olswold, C., Slettedahl, S., Hallberg, E., Guidugli, L., Davila, J. I., Beckmann, M. W., Janni, W., Rack, B., Ekici, A.

- B., Slamon, D. J., ... Fasching, P. A. (2015). Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. *Journal of Clinical Oncology*, 33(4), 304–311. <https://doi.org/10.1200/JCO.2014.57.1414>
- Dansonka-Mieszkowska, A., Kluska, A., Moes, J., Dabrowska, M., Nowakowska, D., Niwinska, A., Derlatka, P., Cendrowski, K., & Kupryjanczyk, J. (2010). A novel germline *PALB2* deletion in Polish breast and ovarian cancer patients. *BMC Medical Genetics*, 11(1), 20. <https://doi.org/10.1186/1471-2350-11-20>
- De Bruin, M. A., Ford, J. M., & Kurian, A. W. (2012). Genetic polymorphisms as predictors of breast cancer risk. *Current Breast Cancer Reports*, 4(4), 232–239. <https://doi.org/10.1007/s12609-012-0091-7>
- Dianatopur, A., Faramarzi, S., & Ghafouri-Fard, S. (2018). Meta-analysis of association between *PALB2* polymorphisms and breast cancer. *Asian Pacific Journal of Cancer Prevention*, 19(10). <https://doi.org/10.22034/APJCP.2018.19.10.2897>
- Fulawka, L., & Halon, A. (2017). Ki-67 evaluation in breast cancer: The daily diagnostic practice. *Indian Journal of Pathology and Microbiology*, 60(2), 177. https://doi.org/10.4103/IJPM.IJPM_732_15
- Gallagher, S. (1998). Quantitation of Nucleic Acids with Absorption Spectroscopy. In J. E. Coligan, B. M. Dunn, D. W. Speicher, & P. T. Wingfield (Eds.), *Current Protocols in Protein Science* (p. A.4K.1-A.4K.3). John Wiley & Sons, Inc. <https://doi.org/10.1002/0471140864.psa04ks13>
- Garibyan, L., & Avashia, N. (2013). Polymerase chain reaction. *Journal of Investigative Dermatology*, 133(3), 1–4. <https://doi.org/10.1038/jid.2013.1>
- Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., Bonnefoi, H., Bretel-Morales, D., Burstein, H., Cardoso, F., Castiglione-Gertsch, M., Coates, A. S., Colleoni, M., Costa, A., Curigliano, G., ... Wood, W. C. (2013). Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Annals of Oncology*, 24(9), 2206–2223. <https://doi.org/10.1093/annonc/mdt303>
- Green, M., & Raina, V. (2008). Epidemiology, screening and diagnosis of breast cancer in the Asia-Pacific region: current perspectives and important considerations. *Asia-Pacific Journal of Clinical Oncology*, 4, S5–S13. <https://doi.org/10.1111/j.1743-7563.2008.00191.x>
- Guénard, F., Pedneault, C. S.-L., Ouellette, G., Labrie, Y., Simard, J., & Durocher, F. (2010). Evaluation of the contribution of the three breast cancer susceptibility genes *CHEK2*, *STK11*, and *PALB2* in non-*BRCA1/2* French Canadian families with high risk of breast cancer. *Genetic Testing and Molecular Biomarkers*, 14(4), 515–526. <https://doi.org/10.1089/gtmb.2010.0027>
- Haroon, S., Hashmi, A. A., Khurshid, A., Kanpurwala, M. A., Mujtuba, S., Malik, B., & Faridi, N. (2013). Ki67 Index in breast cancer: correlation with other prognostic markers and potential in Pakistani patients. *Asian Pacific Journal of Cancer Prevention*, 14(7), 4353–4358. <https://doi.org/10.7314/APJCP.2013.14.7.4353>

- Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. *Journal of Clinical Oncology*, 25(33), 5287–5312. <https://doi.org/10.1200/JCO.2007.14.2364>
- Hicks, D. G., & Lester, S. C. (2016). *Breast* (2. Edition). Elsevier.
- Huang, T., Shu, Y., & Cai, Y.-D. (2015). Genetic differences among ethnic groups. *BMC Genomics*, 16(1), 1093. <https://doi.org/10.1186/s12864-015-2328-0>
- Huo, D., Zheng, Y., Ogundiran, T. O., Adebamowo, C., Nathanson, K. L., Domchek, S. M., Rebbeck, T. R., Simon, M. S., John, E. M., Hennis, A., Nemesure, B., Wu, S.-Y., Leske, M. C., Ambs, S., Niu, Q., Zhang, J., Cox, N. J., & Olopade, O. I. (2012). Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. *Carcinogenesis*, 33(4), 835–840. <https://doi.org/10.1093/carcin/bgs093>
- Hu, Z.-Y., Liu, L., Xie, N., Lu, J., Liu, Z., Tang, Y., Wang, Y., Yang, J., & Ouyang, Q. (2020). Germline *PALB2* mutations in cancers and its distinction from somatic *PALB2* mutations in breast cancers. *Frontiers in Genetics*, 11, 829. <https://doi.org/10.3389/fgene.2020.00829>
- Inwald, E. C., Klinkhammer-Schalke, M., Hofstädter, F., Zeman, F., Koller, M., Gerstenhauer, M., & Ortmann, O. (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. *Breast Cancer Research and Treatment*, 139(2), 539–552. <https://doi.org/10.1007/s10549-013-2560-8>
- Iqbal, N., & Iqbal, N. (2014). Human Epidermal Growth Factor Receptor 2 (HER2) in cancers: overexpression and therapeutic implications. *Molecular Biology International*, 2014, 1–9. <https://doi.org/10.1155/2014/852748>
- Jiang, W., Zhuang, C., Zheng, L., & Wang, X. (2016). Role of *PALB2* polymorphisms with regard to susceptibility to female breast cancer risk in the Chinese Population. *Genetic Testing and Molecular Biomarkers*, 20(5), 229–234. <https://doi.org/10.1089/gtmb.2015.0303>
- Kementerian Kesehatan RI. 2019. *Hari kanker dedunia 2019*. <https://www.kemkes.go.id/index.php?pg=brokenlink>. Accessed March 27 2022.
- Kobayashi, T., Iwaya, K., Moriya, T., Yamasaki, T., Tsuda, H., Yamamoto, J., & Matsubara, O. (2013). A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer. *BMC Clinical Pathology*, 13(1), 5. <https://doi.org/10.1186/1472-6890-13-5>
- Kontzoglou, K., Palla, V., Karaolanis, G., Karaikos, I., Alexiou, I., Pateras, I., Konstantoudakis, K., & Stamatakis, M. (2013). Correlation between Ki67 and breast cancer prognosis. *Oncology*, 84(4), 219–225. <https://doi.org/10.1159/000346475>
- Kraus, C., Hoyer, J., Vasileiou, G., Wunderle, M., Lux, M. P., Fasching, P. A., Krumbiegel, M., Uebe, S., Reuter, M., Beckmann, M. W., & Reis, A. (2017). Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than *BRCA1/2*: Gene panel sequencing in familial breast/ovarian cancer patients [AQ].

- International Journal of Cancer*, 140(1), 95–102.
<https://doi.org/10.1002/ijc.30428>
- Kumar, V., Abbas, A. K., Aster, J. C., & Perkins, J. A. (Eds.). (2021). *Robbins & Cotran pathologic basis of disease* (Tenth edition). Elsevier.
- Kurian, A. W., Fish, K., Shema, S. J., & Clarke, C. A. (2010). Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. *Breast Cancer Research*, 12(6), R99. <https://doi.org/10.1186/bcr2780>
- Kutomi, G., Mizuguchi, T., Satomi, F., Maeda, H., Shima, H., Kimura, Y., & Hirata, K. (2017). Current status of the prognostic molecular biomarkers in breast cancer: a systematic review. *Oncology Letters*, 13(3), 1491–1498. <https://doi.org/10.3892/ol.2017.5609>
- Laraqui, A., Cavaillé, M., Uhrhammer, N., ElBiad, O., Bidet, Y., El Rhaffouli, H., El Anaz, H., Rahali, D. M., Kouach, J., Guelzim, K., Badaoui, B., AlBouzidi, A., Oukabli, M., Tanz, R., Sbitti, Y., Ichou, M., Ennibi, K., Sekhsokh, Y., & Bignon, Y.-J. (2021). Identification of a novel pathogenic variant in *PALB2* and *BARD1* genes by a multigene sequencing panel in triple negative breast cancer in Morocco. *Journal of Genomics*, 9, 43–54. <https://doi.org/10.7150/jgen.61713>
- Leong, S. P. L., Shen, Z.-Z., Liu, T.-J., Agarwal, G., Tajima, T., Paik, N.-S., Sandelin, K., Derossis, A., Cody, H., & Foulkes, W. D. (2010). Is breast cancer the same disease in Asian and Western countries? *World Journal of Surgery*, 34(10), 2308–2324. <https://doi.org/10.1007/s00268-010-0683-1>
- Lester, S. C., Bose, S., Chen, Y.-Y., Connolly, J. L., De Baca, M. E., Fitzgibbons, P. L., Hayes, D. F., Kleer, C., O'Malley, F. P., Page, D. L., Smith, B. L., Tan, L. K., Weaver, D. L., & Winer, E. (2009). Protocol for the examination of specimens from patients with invasive carcinoma of the breast. *Archives of Pathology & Laboratory Medicine*, 133(10), 1515–1538. <https://doi.org/10.5858/133.10.1515>
- Li, A., Geyer, F. C., Blecula, P., Lee, J. Y., Selenica, P., Brown, D. N., Pareja, F., Lee, S. S. K., Kumar, R., Rivera, B., Bi, R., Piscuoglio, S., Wen, H. Y., Lozada, J. R., Gularte-Mérida, R., Cavallone, L., Rezoug, Z., Nguyen-Dumont, T., Peterlongo, P., ... Young, M. A. (2019). Homologous recombination DNA repair defects in *PALB2*-associated breast cancers. *Npj Breast Cancer*, 5(1), 23. <https://doi.org/10.1038/s41523-019-0115-9>
- Li, W.-H., Gu, Z., Wang, H., & Nekrutenko, A. (2001). Evolutionary analyses of the human genome. *Nature*, 409(6822), 847–849. <https://doi.org/10.1038/35057039>
- Liao, P.-Y., & Lee, K. H. (2010). From SNPs to functional polymorphism: The insight into biotechnology applications. *Biochemical Engineering Journal*, 49(2), 149–158. <https://doi.org/10.1016/j.bej.2009.12.021>
- Lim, Y. X., Lim, Z. L., Ho, P. J., & Li, J. (2022). Breast cancer in Asia: incidence, mortality, early detection, mammography programs, and risk-based screening initiatives. *Cancers*, 14(17), 4218. <https://doi.org/10.3390/cancers14174218>
- Listyawardhani, Y., Mudigdo, A., & Adrian, R. B. (2018). Risk factors of breast cancer in women at Dr. Moewardi Hospital, Surakarta, Central Java. *Journal of Epidemiology and Public Health*, 03(02), 118–127. <https://doi.org/10.26911/jepublichealth.2018.03.02.02>

- Lonetti, A., Fontana, M. C., Martinelli, G., & Iacobucci, I. (2016). Single Nucleotide Polymorphisms as Genomic Markers for High-Throughput Pharmacogenomic Studies. In P. C. H. Li, A. Sedighi, & L. Wang (Eds.), *Microarray Technology* (Vol. 1368, pp. 143–159). Springer New York. https://doi.org/10.1007/978-1-4939-3136-1_11
- Lucena-Aguilar, G., Sánchez-López, A. M., Barberán-Aceituno, C., Carrillo-Ávila, J. A., López-Guerrero, J. A., & Aguilar-Quesada, R. (2016). DNA source selection for downstream applications based on dna quality indicators analysis. *Biopreservation and Biobanking*, 14(4), 264–270. <https://doi.org/10.1089/bio.2015.0064>
- Mahdi, A., Ibrahim, H., & Mohammed, A. (2018). Ki-67 expression as an indicator of invasiveness in patients with breast cancer. *Medical Journal of Babylon*, 15(4), 271. https://doi.org/10.4103/MJBL.MJBL_54_18
- Makki, J. (2015). Diversity of breast carcinoma: histological subtypes and clinical relevance. *Clinical Medicine Insights: Pathology*, 8, CPath.S31563. <https://doi.org/10.4137/CPath.S31563>
- Malhotra, G. K., Zhao, X., Band, H., & Band, V. (2010). Histological, molecular and functional subtypes of breast cancers. *Cancer Biology & Therapy*, 10(10), 955–960. <https://doi.org/10.4161/cbt.10.10.13879>
- Maughan, K. L., Lutterbie, M. A., & Ham, P. S. (2010). Treatment of breast cancer. *American Family Physician*, 81(11), 1339–1346.
- Miah, S., Bagu, E., Goel, R., Ogunbolude, Y., Dai, C., Ward, A., Vizeacoumar, F. S., Davies, G., Vizeacoumar, F. J., Anderson, D., & Lukong, K. E. (2019). Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells. *BMC Cancer*, 19(1), 78. <https://doi.org/10.1186/s12885-018-5186-8>
- Mishra, S., Sable, M., Das Majumdar, S., Mishra, P., Muduly, D., & Parida, D. (2022). Bilateral breast cancer—Its clinicopathological profile and management: An experience from a tertiary care center from Eastern India. *Journal of Cancer Research and Therapeutics*, 18(9), 341. https://doi.org/10.4103/jcrt.JCRT_1729_20
- Mohammed, A. A. (2019a). Predictive factors affecting axillary lymph node involvement in patients with breast cancer in Duhok: cross-sectional study. *Annals of Medicine and Surgery*, 44, 87–90. <https://doi.org/10.1016/j.amsu.2019.07.011>
- Mohammed, A. A. (2019b). Quantitative assessment of Ki67 expression in correlation with various breast cancer characteristics and survival rate; cross sectional study. *Annals of Medicine and Surgery*, 48, 129–134. <https://doi.org/10.1016/j.amsu.2019.11.005>
- Mohan, H. (2015). *Textbook of pathology* (Seventh edition). Jaypee Brothers Medical Publishers.
- Murrell, D. H., Foster, P. J., & Chambers, A. F. (2014). Brain metastases from breast cancer: Lessons from experimental magnetic resonance imaging studies and clinical implications. *Journal of Molecular Medicine*, 92(1), 5–12. <https://doi.org/10.1007/s00109-013-1108-z>
- Nawar, N. (2021). Structure analysis of deleterious nsSNPs in human *PALB2* protein for functional inference. *Bioinformation*, 17(3), 424–438. <https://doi.org/10.6026/97320630017424>

- Ng, P. S., Pan, J. W., Ahmad Zabidi, M. M., Rajadurai, P., Yip, C. H., Reuda, O. M., Dunning, A. M., Antoniou, A. C., Easton, D. F., Caldas, C., Chin, S.-F., & Teo, S. H. (2021). Characterisation of *PALB2* tumours through whole-exome and whole-transcriptomic analyses. *Npj Breast Cancer*, 7(1), 46. <https://doi.org/10.1038/s41523-021-00254-4>
- Nickoloff, J. A. (2017). Mechanisms of Chromosome Translocations in Cancer. In John Wiley & Sons, Ltd (Ed.), *Encyclopedia of Life Sciences* (1st ed., pp. 1–7). Wiley. <https://doi.org/10.1002/9780470015902.a0026853>
- Nicolini, A., Ferrari, P., & Duffy, M. J. (2018). Prognostic and predictive biomarkers in breast cancer: Past, present and future. *Seminars in Cancer Biology*, 52, 56–73. <https://doi.org/10.1016/j.semcancer.2017.08.010>
- Olson, N. D., & Morrow, J. B. (2012). DNA extract characterization process for microbial detection methods development and validation. *BMC Research Notes*, 5(1), 668. <https://doi.org/10.1186/1756-0500-5-668>
- Paluch-Shimon, S., Cardoso, F., Sessa, C., Balmana, J., Cardoso, M. J., Gilbert, F., & Senkus, E. (2016). Prevention and screening in *BRCA* mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. *Annals of Oncology*, 27, v103–v110. <https://doi.org/10.1093/annonc/mdw327>
- Parsa, Y., Mirmalek, S. A., Elham Kani, F., Aidun, A., Salimi-Tabatabaee, S. A., Yadollah-Damavandi, S., Jangholi, E., Parsa, T., & Shahverdi, E. (2016). A review of the clinical implications of breast cancer biology. *Electronic Physician*, 8(5), 2416–2424. <https://doi.org/10.19082/2416>
- Passarge, E. (2013). *Color atlas of genetics* (4th ed., rev.updated). New York : Thieme.
- Peng, L., Zhang, Z., Zhao, D., Zhao, J., Mao, F., & Sun, Q. (2021). Discordance in ER, PR, HER2, and Ki-67 expression between primary and recurrent/metastatic lesions in patients with primary early stage breast cancer and the clinical significance: retrospective analysis of 75 cases. *Pathology and Oncology Research*, 27, 599894. <https://doi.org/10.3389/pore.2021.599894>
- Popovici, C., Basset, C., Bertucci, F., Orsetti, B., Adélaide, J., Mozziconacci, M.-J., Conte, N., Murati, A., Ginestier, C., Charafe-Jauffret, E., Ethier, S. P., Lafage-Pochitaloff, M., Theillet, C., Birnbaum, D., & Chaffanet, M. (2002). Reciprocal translocations in breast tumor cell lines: Cloning of a t(3;20) that targets the FHIT gene: reciprocal translocations in breast cancer cell lines. *Genes, Chromosomes and Cancer*, 35(3), 204–218. <https://doi.org/10.1002/gcc.10107>
- Privitera, A. P., Barresi, V., & Condorelli, D. F. (2021). Aberrations of chromosomes 1 and 16 in breast cancer: a framework for cooperation of transcriptionally dysregulated genes. *Cancers*, 13(7), 1585. <https://doi.org/10.3390/cancers13071585>
- Purdie, C. A., Quinlan, P., Jordan, L. B., Ashfield, A., Ogston, S., Dewar, J. A., & Thompson, A. M. (2014). Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. *British Journal of Cancer*, 110(3), 565–572. <https://doi.org/10.1038/bjc.2013.756>

- Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2010). Combinatorial biomarker expression in breast cancer. *Breast Cancer Research and Treatment*, 120(2), 293–308. <https://doi.org/10.1007/s10549-010-0746-x>
- Rosai, J. (2011). *Rosai and ackerman's surgical pathology* (10th ed.). Elsevier.
- Ripperger, T., Gadzicki, D., Meindl, A., & Schlegelberger, B. (2009). Breast cancer susceptibility: current knowledge and implications for genetic counselling. *European Journal of Human Genetics*, 17(6), 722–731. <https://doi.org/10.1038/ejhg.2008.212>
- Sambrook, J., Russell, D. W., & Sambrook, J. (2006). *The Condensed Protocols from Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press.
- Shaath, H., Elango, R., & Alaje, N. M. (2021). Molecular classification of breast cancer utilizing long non-coding RNA (lncRNA) transcriptomes identifies novel diagnostic lncRNA panel for triple-negative breast cancer. *Cancers*, 13(21), 5350. <https://doi.org/10.3390/cancers13215350>
- Shiovitz, S., & Korde, L. A. (2015). Genetics of breast cancer: a topic in evolution. *Annals of Oncology*, 26(7), 1291–1299. <https://doi.org/10.1093/annonc/mdv022>
- Tan, P. H., & Sahin, A. A. (2017). *Atlas of Differential Diagnosis in Breast Pathology*. Springer.
- Tedjamartono, T. D., Sudarsa, I. W., Winata, A., & Wetan, N. G. A. A. M. Y. (2020). Overekspresi HER-2 sebagai faktor risiko terjadinya metastasis otak pada pasien kanker payudara. *E-Jurnal Medika Udayana*, 9(9), 58–64. <https://doi.org/10.24843/MU.2020.V09.i9.P10>
- Thomas, P. A. (Ed.). (2011). *Breast cancer and its precursor lesions: making sense and making it early*. Humana Press. <https://doi.org/10.1007/978-1-60327-154-7>
- Trisna, W. A., Sahudi, S., & Kusumastuti, E. H. (2021). Correlation between hormonal status of estrogen receptor and malignancy degree of invasive ductal breast cancer. *Majalah Biomorfologi*, 31(1), 1. <https://doi.org/10.20473/mbiom.v31i1.2021.1-5>
- Vallejos-Vidal, E., Reyes-Cerpa, S., Rivas-Pardo, J. A., Maisey, K., Yáñez, J. M., Valenzuela, H., Cea, P. A., Castro-Fernandez, V., Tort, L., Sandino, A. M., Imarai, M., & Reyes-López, F. E. (2020). Single-Nucleotide Polymorphisms (SNP) mining and their effect on the tridimensional protein structure prediction in a set of immunity-related Expressed Sequence Tags (EST) in Atlantic Salmon (*Salmo salar*). *Frontiers in Genetics*, 10, 1406. <https://doi.org/10.3389/fgene.2019.01406>
- Vaz-Luis, I., Winer, E. P., & Lin, N. U. (2013). Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? *Annals of Oncology*, 24(2), 283–291. <https://doi.org/10.1093/annonc/mds286>
- Watkins, E. J. (2019). Overview of breast cancer. *JAAPA*, 32(10), 13–17. <https://doi.org/10.1097/01.JAA.0000580524.95733.3d>
- Wittmeier, P., & Hummel, S. (2022). Agarose gel electrophoresis to assess PCR product yield: comparison with spectrophotometry, fluorometry and qPCR. *BioTechniques*, 72(4), 155–158. <https://doi.org/10.2144/btn-2021-0094>

- Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., Hanna, W., Jenkins, R. B., Mangu, P. B., Paik, S., Perez, E. A., Press, M. F., Spears, P. A., Vance, G. H., Viale, G., & Hayes, D. F. (2013). Recommendations for Human Epidermal Growth Factor Receptor 2 testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *Journal of Clinical Oncology*, 31(31), 3997–4013. <https://doi.org/10.1200/JCO.2013.50.9984>
- Wong, R. S. (2011). Apoptosis in cancer: from pathogenesis to treatment. *Journal of Experimental & Clinical Cancer Research*, 30(1), 87. <https://doi.org/10.1186/1756-9966-30-87>
- Wong-Brown, M. W., Avery-Kiejda, K. A., Bowden, N. A., & Scott, R. J. (2014). Low prevalence of germline *PALB2* mutations in Australian triple-negative breast cancer: low prevalence of germline *PALB2* mutations. *International Journal of Cancer*, 134(2), 301–305. <https://doi.org/10.1002/ijc.28361>
- Wu, S., Zhou, J., Zhang, K., Chen, H., Luo, M., Lu, Y., Sun, Y., & Chen, Y. (2020). Molecular mechanisms of *PALB2* function and its role in breast cancer management. *Frontiers in Oncology*, 10, 301. <https://doi.org/10.3389/fonc.2020.00301>
- Wu, Y., Dong, X., Wang, Y., Wang, Q., Gu, H., & Huang, W. (2018). Association between rs120963, rs152451, rs249935, rs447529, rs8053188, and rs16940342 Polymorphisms in the *PALB2* gene and breast cancer susceptibility: a meta-analysis. *Oncology Research and Treatment*, 41(12), 780–786. <https://doi.org/10.1159/000492827>
- Yüksel BiLen, M., Berköz, M., Yalin, A. E., Çalikuşu, Z., Eroğlu, P., Çömelekoğlu, Ü., & Yalin, S. (2020). Investigation of effects of *PALB2* genetic variations on breast cancer predisposition. *Cukurova Medical Journal*, 45(1), 186–194. <https://doi.org/10.17826/cumj.634598>
- Zhang, K., Zhou, J., Zhu, X., Luo, M., Xu, C., Yu, J., Deng, M., Zheng, S., & Chen, Y. (2017). Germline mutations of *PALB2* gene in a sequential series of Chinese patients with breast cancer. *Breast Cancer Research and Treatment*, 166(3), 865–873. <https://doi.org/10.1007/s10549-017-4425-z>
- Zhang, M. H., Man, H. T., Zhao, X. D., Dong, N., & Ma, S. L. (2014). Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). *Biomedical Reports*, 2(1), 41–52. <https://doi.org/10.3892/br.2013.187>